Related Experiment Video
Updated: Jan 18, 2026

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study
Oh Chan Kwon1, Hye Sun Lee2, So Young Jeon2
1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Objective:
To investigate the effect of tumour necrosis factor inhibitors (TNFi) on the risk of cancer recurrence in patients with AS and a history of cancer.
Methods:
We conducted a nested case-control study using a cohort derived from a nationwide database. The cohort consisted of patients with AS and a history of cancer after AS diagnosis. We determined cases of cancer recurrence and selected controls at a ratio of 1:1, matched for age, sex, date of index cancer diagnosis and follow-up time. Multivariable conditional logistic regression analysis was used to assess the effect of TNFi exposure on the risk of cancer recurrence.
Results:
A total of 2574 patients with AS and a history of cancer were included in the cohort. Among these, cancer recurred in 394 (15.3%) patients. The incidence rate of cancer recurrence was 4.87 (95% CI 4.40-5.34)/100 person-years. From this cohort, 254 cases and age-, sex-, index date- and follow-up time-matched 254 controls were included for the nested case-control study. The proportion of patients exposed to TNFi did not differ between the cases and controls (24.8% vs 24.4%, P = 0.918). In the multivariable conditional logistic regression analysis, TNFi exposure was not associated with an increased risk of cancer recurrence (adjusted odds ratio 1.157, 95% CI 0.734-1.825, P = 0.531).
Conclusion:
TNFi exposure was not associated with an increased risk of cancer recurrence in patients with AS. Our findings suggest that TNFi may be used with caution in patients with AS and a history of cancer.
More Related Videos
16:07Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
The JAK-STAT Signaling Pathway
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents